Skye Bioscience, Inc. is set to acquire Redx Pharma Limited in a significant merger that will transform its business landscape. The agreement, filed on October 28, 2026, signals a strategic shift for Skye as it aims to enhance its focus on fibrosis treatments. This merger not only promises to reshape Skye's operations but also reflects the broader consolidation trends within the pharmaceutical preparations industry.

Background

Skye Bioscience, Inc. is a Nevada-based company specializing in pharmaceutical preparations, trading under the ticker SKYE on the Nasdaq. The company has undergone several name changes, previously known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc. Skye has been actively involved in various filings, including its recent PRER14A submission, which highlights its plans for the future.

What the Filing Says

The filing outlines the terms of the merger, stating, "Skye will acquire the entire issued and to be issued share capital of Redx pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006." This acquisition is expected to provide Skye stockholders with equity in a Nasdaq-listed, fibrosis-focused company, alongside contingent value rights related to the monetization of nimacimab.

Impact

The merger will significantly affect both companies' stakeholders. Skye's stockholders will gain an interest in a company with a funded Phase 2 program, while Redx shareholders will see their investments transition into a larger, Nasdaq-listed entity. The combined company, which will be renamed Fibrx Therapeutics, Inc., will be led by Redx's current management team, aiming to accelerate the development of fibrosis programs.

What's Next

The filing indicates that a Special Meeting of Stockholders will be held to vote on the merger and related proposals. Skye's Board of Directors unanimously recommends that stockholders vote in favor of the transaction, emphasizing its importance for the future of the company. The outcome of this vote will determine the next steps for both Skye and Redx as they move forward with the merger.